Introduction:

The etiopathogeneses of this type of tumor is related to age, genetic, viral and environmental factors (ultraviolet radiation). It initially presents as a small, slow-growing tumor, as an ulcerated lesion, with telangiectasias and a rounded border, and its signs may vary according to the clinical subtype.

Objective:

to clinic-epidemiologically characterize patients over 20 years of age with basal cell carcinoma in the facial region treated with HeberFERON®.

Methods:

a descriptive retrospective cross-sectional study was conducted in patients over 20 years of age with basal cell carcinoma (BCC) in the facial region of the General Teaching Hospital "Dr. Ernesto Guevara de la Serna", in the period 2020-2021. The universe consisted of 47 patients with basal cell carcinoma and with confirmatory biopsy of the lesion. The sample was represented by 33 patients who met the inclusion criteria, obtained by non-probabilistic purposive sampling.

Results:

The male sex predominated with 66,7 %, the 76-85 age group was the most representative with 45,5 %. The nose was the anatomical site with the highest incidence. Fever and chills were the most frequent adverse reactions. Fainting was the main symptom and a complete response to treatment was observed in most of the study sample.

Conclusions:

HeberFERON® enables a higher success rate in the treatment of multiple carcinomatosis and extensive lesions, as it is prescribed as an essential complement to the surgical procedure.

        · |     · |     · ( pdf )